Compare OTTR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OTTR | ACAD |
|---|---|---|
| Founded | 1907 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | 2009 | 2000 |
| Metric | OTTR | ACAD |
|---|---|---|
| Price | $86.23 | $21.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 22 |
| Target Price | N/A | ★ $30.55 |
| AVG Volume (30 Days) | 225.5K | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.69% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 6.55 | 2.30 |
| Revenue | ★ $1,299,640,000.00 | $726,437,000.00 |
| Revenue This Year | $1.99 | $18.80 |
| Revenue Next Year | $3.83 | $11.70 |
| P/E Ratio | $13.15 | ★ $9.45 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $73.74 | $14.08 |
| 52 Week High | $92.24 | $28.35 |
| Indicator | OTTR | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 49.16 |
| Support Level | $84.22 | $21.51 |
| Resistance Level | $89.87 | $22.03 |
| Average True Range (ATR) | 2.05 | 0.70 |
| MACD | -0.23 | 0.08 |
| Stochastic Oscillator | 18.81 | 57.43 |
Otter Tail Corp is a U.S. energy company that operates in the electric (produces and sells electricity), manufacturing (fabricates metal components), and plastics segments (pipes for water uses). The company conducts its operations and acquires the majority of its revenue in the U.S. in the states of Minnesota, South Dakota, and North Dakota. The majority of the company's revenue is derived from the Electric segment and commercial customers, although it generates revenue from residential and industrial customers, as well.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.